Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
Exact Sciences: Q3 Sell-Off May Be Unjustified, But Long-Term Outlook A Concern
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
Exact Sciences price target lowered to $75 from $95 at Canaccord
Canaccord analyst Kyle Mikson lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $95 and keeps a Buy rating on the ...
Investing14d
Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT
The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product. The analyst ...
Investing14d
Canaccord Genuity sees upside potential for Exact Sciences shares, lifts PT
The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product.
Pharmabiz14d
Exact Sciences presents multiple studies at ACG 2024; demonstrating leadership in noninvasive colorectal cancer screening and patient engagement
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has announced the company presenting modeling data evaluating the simulated benefit and burden of established CRC ...
pharmaphorum15d
Exact Sciences buys cancer detection company Thrive for $2.15 billion
Exact Sciences, which is behind brands Cologuard and Oncotype DX, said it will combine CancerSEEK with its scientific platform, clinical organization, and commercial infrastructure. The company ...